Drug induced chorea
Conditions
Interventions
This is an open-label, uncontrolled, single arm trial in which we will use doxycycline (200mg/day orally) for 12 weeks in 10 patients diagnosed with Parkinson's disease to see if the treatment can red
SP4.022.238.359
Sponsors
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients 18 years of age or older; diagnosed with Parkinson's disease according to the United Kingdon Parkinson's Disease Society Brain Bank clinical diagnostic criteria; presenting at the initial evaluation with at least some functional impact dyskinesias (score higer than1 on item 4. 2 of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS); who are using levodopa at least three times a day; and who can keep doses of antiparkinsonian medications unchanged for at least four weeks prior to screening and during study participation.
Exclusion criteria
Exclusion criteria: Diagnosis of atypical or secondary parkinsonism; treatment of any experimental drug or other intervention within 90 days prior to screening or baseline assessment; presence of moderate or severe psychotic symptoms (score greater than 2 on item 1. 2 of the Movement Disorders Society's Unified Scale for Assessment of Parkinson`s disease; diagnosis of dementia according to the Movement Disorders Society diagnostic criteria; suffering from serious systemic conditions (infections, malignancies, chronic kidney or liver disease); pregnancy or lactation; history of hypersensitivity or allergic reaction to tetracyclines; absence of clinical dyskinetic movements at baseline assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to observe a significant reduction in dyskinesia clinical assessment scores according to the Unified Dyskinesia Rating Scale between the baseline assessment and the assessment after 12 weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to observe a significant reduction in the time with disabling dyskinesias in the motor status diary between the baseline assessment and the assessment after 12 weeks of treatment. | — |
Countries
Brazil
Contacts
Public ContactVitor Tumas
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Outcome results
None listed